ATE369375T1 - Synthese von locked nucleic acid-derivaten - Google Patents

Synthese von locked nucleic acid-derivaten

Info

Publication number
ATE369375T1
ATE369375T1 AT03718663T AT03718663T ATE369375T1 AT E369375 T1 ATE369375 T1 AT E369375T1 AT 03718663 T AT03718663 T AT 03718663T AT 03718663 T AT03718663 T AT 03718663T AT E369375 T1 ATE369375 T1 AT E369375T1
Authority
AT
Austria
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
AT03718663T
Other languages
English (en)
Inventor
Mads Sorensen
Jesper Wengel
Troels Koch
Signe Christensen
Christoph Rosenbohm
Daniel Sejer Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of ATE369375T1 publication Critical patent/ATE369375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03718663T 2002-05-08 2003-05-08 Synthese von locked nucleic acid-derivaten ATE369375T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16

Publications (1)

Publication Number Publication Date
ATE369375T1 true ATE369375T1 (de) 2007-08-15

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718663T ATE369375T1 (de) 2002-05-08 2003-05-08 Synthese von locked nucleic acid-derivaten

Country Status (9)

Country Link
EP (1) EP1501848B1 (de)
JP (1) JP4476802B2 (de)
AT (1) ATE369375T1 (de)
AU (1) AU2003222743B2 (de)
CA (1) CA2484526C (de)
DE (1) DE60315444T2 (de)
DK (1) DK1501848T3 (de)
ES (1) ES2290448T3 (de)
WO (1) WO2003095467A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
EP2752488B1 (de) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Antisense-Entwurf
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
EP2141234B1 (de) 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Analoga kurzer interferierender RNA (SIRNA)
NZ548254A (en) 2003-12-23 2008-09-26 Santaris Pharma As Oligomeric compounds for the modulation of BCL-2
CA2587173C (en) 2004-11-09 2016-09-06 Santaris Pharma A/S Potent lna oligonucleotides for the inhibition of hif-1a expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP1824975B9 (de) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna-oligonukleotide und krebsbehandlung
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
EP2002004B1 (de) 2006-03-23 2015-10-14 Roche Innovation Center Copenhagen A/S Kleine intern segmentierte interferenz-rna
PL2666859T3 (pl) 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
WO2008006369A1 (en) * 2006-07-14 2008-01-17 Santaris Pharma A/S Adenosine receptor antagonists
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2126079A1 (de) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna-antagonistenverbindungen zur hemmung der apo-b100-expression
EP2173373B1 (de) 2007-06-06 2020-04-15 Sarepta Therapeutics, Inc. Lösliche her2- und her3-spleissvariantenproteine, spleissschaltende oligonukleotide und deren verwendung bei der behandlung von krankheiten
EP2183360B1 (de) 2007-08-30 2017-01-11 Hadasit Medical Research Services&Development Company Ltd. Nukleinsäuresequenzen mit nf-(kappa)b-bindungsstelle innerhalb eines o(6)-methylguanin-dna-methyltransferase (mgmt)-promoter-bereichs und ihre verwendung zur behandlung von krebs und immunbedingten erkrankungen
EP2548962B1 (de) 2007-09-19 2016-01-13 Applied Biosystems, LLC Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
EP2542678B1 (de) 2010-03-04 2017-04-12 InteRNA Technologies B.V. Mirna-molekül, das durch seine quelle definiert ist, und seine therapeutischen verwendungen bei emt assoziierten krebs
EP3369817A1 (de) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna und ihre diagnostischen und therapeutischen verwendungen bei erkrankungen und zuständen im zusammenhang mit melanomen oder bei erkrankungen und zuständen mit einem aktivierten braf-pfad
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
EP2734553B1 (de) * 2011-07-21 2019-04-17 Rhodia Opérations hAARBEHANDLUNGSZUSAMMENSETZUNGEN ENTHALTEND KATIONISCHE GUAR-DERIVATE
EP2794881B1 (de) 2011-12-22 2018-06-27 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
US10731154B2 (en) 2015-02-15 2020-08-04 Arcturus Therapeutics, Inc. Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
EP3390636B1 (de) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense-oligomere zur behandlung von dravet-syndrom
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US11390867B2 (en) 2016-04-29 2022-07-19 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
EP3494219A1 (de) 2016-08-03 2019-06-12 Aalborg Universitet Zur hemmung von immun-checkpoint-proteinen designte antisense-oligonukleotide (aso)
EP3673080B1 (de) 2017-08-25 2023-10-18 Stoke Therapeutics, Inc. Antisense-oligomere zur behandlung von leiden und krankheiten
EP3704250A1 (de) 2017-11-03 2020-09-09 InteRNA Technologies B.V. Mirna-molekül, äquivalent, antagomir oder quelle davon zur behandlung und/oder diagnose eines zustands und/oder einer erkrankung im zusammenhang mit neuronaler defizienz oder neuronaler (re)generation
AU2019218557A1 (en) 2018-02-12 2020-08-20 Interna Technologies B.V. Anticancer microRNA and lipid formulations thereof
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
CN113748209A (zh) 2019-02-27 2021-12-03 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
AU2022219031A1 (en) 2021-02-12 2023-09-07 Merand Pharmaceuticals, Inc. Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
JP2024510663A (ja) 2021-03-26 2024-03-08 ニューミルナ セラピューティクス エーピーエス マイクロｒｎａ－１３４阻害剤
AU2022242781A1 (en) 2021-03-26 2023-10-26 Neumirna Therapeutics Aps Microrna-27b inhibitors
US20240240188A1 (en) 2021-06-04 2024-07-18 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
KR20240046879A (ko) 2021-08-17 2024-04-11 한국과학기술원 Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도
JP2024531342A (ja) 2021-08-19 2024-08-29 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
EP4332239A1 (de) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
EP4450626A1 (de) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
WO2025015676A1 (zh) * 2023-07-21 2025-01-23 瑞孚医药科技（广州）有限公司 碳环核苷、寡核苷酸及其制备方法和医药用途
EP4512899A1 (de) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4-aso-zusammensetzungen zur behandlung von atherosklerose bei menschen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776362B2 (en) * 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
ATE325806T1 (de) * 2000-10-04 2006-06-15 Santaris Pharma As Verbesserte synthese von purin-blockierten nukleinsäure-analoga

Also Published As

Publication number Publication date
JP4476802B2 (ja) 2010-06-09
CA2484526C (en) 2009-10-13
AU2003222743A1 (en) 2003-11-11
EP1501848B1 (de) 2007-08-08
DK1501848T3 (da) 2007-10-22
DE60315444D1 (en) 2007-09-20
JP2005532319A (ja) 2005-10-27
CA2484526A1 (en) 2003-11-20
ES2290448T3 (es) 2008-02-16
WO2003095467A1 (en) 2003-11-20
DE60315444T2 (de) 2008-04-30
AU2003222743B2 (en) 2008-12-11
EP1501848A1 (de) 2005-02-02

Similar Documents

Publication Publication Date Title
ATE369375T1 (de) Synthese von locked nucleic acid-derivaten
Ali et al. A greener synthetic protocol for the preparation of carbodiimide
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
UA95600C2 (en) Synthesis scheme for lacosamide
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
MY150490A (en) Improved process for producing hydrocyanic acid
WO2005005389A3 (en) Malonamide derivatives
GEP20125512B (en) Process for synthesis of agomelatin
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2009075890A8 (en) Method for synthesis of triazole compounds that modulate hsp90 activity
GB0520085D0 (en) Oligomerisation of olefinic compounds in the presence of an oligomerisation catalyst, and a catalyst activator including a halogenated -AR group
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
US7723495B2 (en) Amidite for nucleic acid synthesis and nucleic acid synthesizing method
PL356929A1 (en) Process for the synthesis of a known tetrazol derivative
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
IL183805A0 (en) Process for preparing substituted thiophenesulfonyl isocyanates
TW200716544A (en) Organic compounds
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
DE60305003D1 (de) Verfahren zur herstellung von synergistischen stabilisatorgemischen
WO2007049295A3 (en) An improved one pot process for making key intermediate for gemcitabine hcl
MY140089A (en) Process for synthesizing (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
Kotikam et al. Synthesis and properties of 2′-O-[R-and S-(2-amino-3-methoxy) propyl](R-AMP and S-AMP) nucleic acids
WO2011161255A3 (en) Processes for the resolution of nitrogen substituted (s) - 5 -alkoxy- 2 -aminotetralin derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties